PROTECT YOUR DNA WITH QUANTUM TECHNOLOGY
Orgo-Life the new way to the future Advertising by AdpathwayA health economics investigation conducted in Italy indicates that generalized pustular psoriasis creates a substantial economic burden from a societal perspective, generating annual costs per patient that considerably surpass those documented for plaque psoriasis while imposing significant impairment on daily living and interpersonal relationships. Generalized pustular psoriasis represents a rare, chronic, and potentially life-threatening inflammatory skin disorder characterized by acute flares of painful erythema studded with sterile pustules, accompanied by systemic manifestations such as high fever, fatigue, chills, and severe peripheral edema. Using a prevalence-based, probabilistic cost-of-illness model built from societal accounting standards, researchers estimated that the total annual burden per diagnosed patient ranges between €24,914 and €25,270, yielding an aggregate national expenditure of approximately €2.94 million to €2.98 million per year based on an estimated national prevalence of 1 to 3 cases per million individuals.
The study sought to resolve critical evidence gaps surrounding the multidimensional economic and human consequences of generalized pustular psoriasis in Italy, where epidemiological consensus estimates an annual incidence of 0.5 to 1 new case per million people alongside a total resident cohort of approximately 118 patients. Although historically viewed as a variant or severe phenotypic subtype of plaque psoriasis, modern genomic and clinical evidence demonstrates that generalized pustular psoriasis is genetically and pathologically distinct. Despite its recognized clinical severity, international economic evaluations have been historically scarce and geographically concentrated within a few jurisdictions such as the United States, Sweden, Japan, Canada, and China, where prior investigations focused almost exclusively on direct medical bills or isolated sick-leave tallies without monetizing comprehensive societal productivity losses or informal caregiver burdens.
To capture all relevant expenditure categories, the investigative team structured a bottom-up prevalence model incorporating direct medical interventions, direct non-medical outlays, and indirect societal productivity impacts evaluated in 2022 euros. Epidemiological baselines and clinical practice pathways were derived from a multidisciplinary synthesis combining published literature, Italian demographic records from the National Institute of Statistics, findings from an expert Delphi consensus panel, and direct consultations with clinical specialists in psoriasis management. To populate granular parameters regarding resource consumption patterns and patient-reported wellbeing, an anonymous socio-economic survey instrument was administered through Qualtrics XM in collaboration with UNIAMO Federazione Italiana Malattie Rare, gathering detailed data spanning medication usage, physician consultations, travel, work impairment, and validated functional disability indices.
Direct healthcare expenditure constituted the primary contributor to overall costs across the modeled scenarios, generating average annual direct medical expenses ranging from €15,645 to €16,021 per patient and totaling between €1.85 million and €1.89 million at the national level. Pharmacological therapy accounted for the overwhelming majority of these direct medical expenditures, representing 93.6 percent in the literature-and-expert driven scenario and 95.8 percent in the survey-based scenario. Because disease-specific therapies such as spesolimab had only recently obtained regulatory clearance during 2024 and lacked established reimbursement lines during the study window, clinical practice relied primarily on off-label biologic and conventional systemic regimens approved for plaque psoriasis. Drug acquisition costs were calculated utilizing official ex-manufacturer wholesale values adjusted for statutory mandatory discounts, with biosimilar market penetration rates explicitly incorporated for key biologic agents including adalimumab and infliximab.
In contrast to the major economic weight of systemic pharmacotherapy, acute hospitalization and emergency department attendances contributed a comparatively modest share of direct clinical expenditures, comprising approximately 3.7 percent of direct healthcare costs in the primary modeling scenario. Inpatient costs were evaluated using official Diagnosis-Related Group tariffs published by the Italian Ministry of Health, while emergency admissions were assigned empirical service tariffs established in national health services literature. Outpatient surveillance represented another steady component of direct medical care, incorporating routine laboratory monitoring scheduled according to European dermatological guidelines as well as specialist consultations and primary care visits, with general practitioner consultation costs quantified at an hourly benchmark of €67.01 derived from Italian medical union benchmarks.
Direct non-healthcare costs, encompassing patient travel expenses and overnight accommodation required for outpatient specialty visits, proved negligible within the total economic picture, amounting to €5,806 in the first scenario and €8,128 in the second. Travel distances to clinical facilities were determined either directly from self-reported patient transport disclosures or estimated through national travel-time metrics to healthcare infrastructure assuming an average transit speed of 50 kilometers per hour. Vehicular travel was monetized using standard Italian motoring reimbursement rates of €0.38 per kilometer. Across both analytical branches, these non-clinical logistics represented less than one percent of the cumulative annual financial burden generated by the condition.
Indirect societal costs formed a substantial portion of the cumulative economic toll, accounting for approximately 36 to 37 percent of the entire societal burden and totaling €1.08 million annually. Lost productivity among patients was valued using the human capital approach applied to Eurostat gross median hourly wage data of €12.61 across an eight-hour workday and an assumed baseline national employment participation rate of 60.8 percent. Patient-level employment losses amounted to €652,301 annually, driven predominantly by workplace presenteeism—defined as on-the-job productivity loss due to active physical or psychological impairment—which averaged 29.62 lost workdays per year. Short-term absenteeism accounted for 3.18 days annually, long-term career absenteeism contributed 2.43 days annually, and unpaid household labor losses added substantial additional economic value under an opportunity-cost valuation framework.
Informal care provided by relatives and unpaid caregivers constituted the remaining 40 percent of total indirect costs, translating to an annual national economic loss of €433,300. Caregivers provided an average of 291.20 hours of supportive assistance per year per patient household, quantified using opportunity-cost principles linked to median wage scales. When compared against historical Italian societal cost benchmarks for plaque psoriasis, the economic impact of generalized pustular psoriasis was markedly higher. Previous societal assessments reported annual per-patient expenditures of €5,226 for moderate and €11,434 for severe plaque psoriasis, which correspond to roughly €7,024 and €15,368 when updated to 2022 price indices. Consequently, managing a patient with generalized pustular psoriasis requires approximately 3.6 times the economic resources of moderate plaque psoriasis and 1.6 times that of severe plaque psoriasis, with indirect burdens demonstrating an even wider divergence.
Deterministic and probabilistic sensitivity analyses confirmed the stability of the baseline economic conclusions while identifying epidemiological frequency as the most influential driver of overall national expenditure. In deterministic tornado evaluations, shifting prevalence across the consensus boundary of 1 to 3 cases per million caused total annual societal outlays to fluctuate between €1.47 million and €4.50 million. The next most sensitive modeling parameters included the proportion of patients receiving anti-interleukin-17 therapies, prevailing gross wage levels, and the quantitative extent of workplace presenteeism. A probabilistic Monte Carlo simulation comprising 1,000 iterative draws yielded mean aggregate expected costs of €3,000,464 under the first scenario and €2,980,718 under the second scenario, confirming that parameter uncertainty remains bounded within narrow expected distributions.
Patient-reported outcomes gathered through the validated Psoriasis Disability Index documented profound physical, functional, and psychological disability across the patient cohort, which recorded a mean cumulative score of 31.8 out of a possible 90 points, indicating an overall perceived functional disability of 35 percent. The functional dimensions exhibiting the highest impairment were daily living activities at 59 percent disability and interpersonal relationships at 42 percent disability. At the granular questionnaire level, respondents identified significant disruptions in managing domestic or gardening chores, the physical necessity of changing or laundering garments frequently, and the social obligation to adjust clothing styles or colors to accommodate active, painful skin lesions and shedding.
The study authors highlighted several methodological limitations that warrant consideration when interpreting the numerical findings. Participant enrollment was conducted via rare disease advocacy networks and specialized clinical channels rather than randomized sampling, yielding a small analytical sample of five complete survey datasets that represents roughly four percent of the national patient cohort. Self-reported survey data carry inherent susceptibility to retrospective recall bias, while therapeutic expenditure models assumed complete pharmacological adherence using list prices that incorporate mandatory legislative discounts but omit confidential institutional rebates. Furthermore, the reliance on gross rather than net hourly wages may slightly overestimate unpaid labor losses, and the cross-sectional survey architecture provides a static appraisal that cannot trace longitudinal fluctuations in flares or health-related quality of life over extended disease trajectories.
Subject of Research: Societal economic burden and health-related quality of life impact of generalized pustular psoriasis in Italy
Article Title: Generalized Pustular Psoriasis: A Cost-of-Illness and Health-Related Quality of Life Study in Italy
Article References: Borsoi, L., Armeni, P., Scopinaro, A. M., Gisondi, P., & Costa, F. (2026). Generalized Pustular Psoriasis: A Cost-of-Illness and Health-Related Quality of Life Study in Italy. PharmacoEconomics – Open, 10(6), 1135-1154. https://doi.org/10.1007/s41669-026-00684-5
Image Credits: AI Generated
DOI: 10.1007/s41669-026-00684-5
Keywords: generalized pustular psoriasis, cost-of-illness, societal perspective, health-related quality of life, Psoriasis Disability Index, dermatology, rare diseases, direct healthcare costs, indirect costs, presenteeism, absenteeism, informal care, plaque psoriasis, health economics, probabilistic sensitivity analysis, Italy


2 hours ago
9




















English (US) ·
French (CA) ·